[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100515182":3},{"organization":4,"armGroups":7,"interventions":13,"overallOfficials":20,"centralContacts":24,"locations":30,"responsibleParty":46,"collaborators":28,"id":49,"slug":28,"hasResults":50,"nctId":51,"briefTitle":52,"officialTitle":53,"acronym":28,"eligibilityCriteria":54,"healthyVolunteers":50,"sex":55,"minAge":56,"maxAge":28,"enrollmentInfo":57,"targetDuration":28,"studyType":60,"phases":61,"briefSummary":63,"conditions":64,"keywords":28,"overallStatus":67,"whyStopped":28,"lastUpdateSubmitDate":68,"lastUpdatePostDateStruct":69,"startDateStruct":72,"completionDateStruct":74,"leadSponsor":76,"locationsCount":77},{"fullName":5,"class":6},"Beijing Friendship Hospital","OTHER",[8],{"label":9,"type":10,"description":9,"interventionNames":11},"Carrimycin tablets","EXPERIMENTAL",[12],"Drug: Carrimycin tablets",[14],{"type":15,"name":9,"description":16,"armGroupLabels":17,"otherNames":18},"DRUG","Carrimycin tablets are administered 400mg a day orally for 7 days.",[9],[19],"Carrimycin",[21],{"name":22,"affiliation":5,"role":23},"Zhao Wang, MD","PRINCIPAL_INVESTIGATOR",[25],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},"CONTACT","63138303",null,"wangzhao@ccmu.edu.cn",[31],{"facility":32,"status":28,"city":33,"state":34,"zip":35,"country":36,"countryCode":37,"cosmosGeoPoint":38,"geoPoint":43,"contacts":44},"Beijing Friendship Hospital, Capital Medical University","Beijing","Beijing Municipality","100050","China","CN",{"type":39,"coordinates":40},"Point",[41,42],116.39723,39.9075,{"lat":42,"lon":41},[45],{"name":22,"role":26,"phone":27,"phoneExt":28,"email":29},{"type":23,"investigatorFullName":47,"investigatorTitle":48,"investigatorAffiliation":5,"oldNameTitle":28,"oldOrganization":28},"Zhao Wang","Professor and Head of hematology","100515182",false,"NCT05988177","Efficacy and Safety of Carrimycin Tablets in HLH Patients With Carbapenem-resistant Infections","Clinical Study on the Efficacy and Safety of Carrimycin Tablets in Hemophagocytic Lymphohistiocytosis Patients With Carbapenem-resistant Infections","Inclusion Criteria:\n\n* Met HLH-2004 diagnostic criteria;\n* Active infection；\n* Empirical treatment with carbapenems did not respond after 72 hours；\n* Age \\>18 years old, no gender limitation;\n* Ability and willingness to adhere to the study visit schedule and all protocol requirements.\n\nExclusion Criteria:\n\n* Other antibiotics should be selected according to the results of drug sensitivity；\n* Systemic antibiotics other than carbapenems are used with 72 hours；\n* Inability to take oral medications due to disease of gastrointestinal tract；\n* Severe liver insufficiency;\n* Expected survival time \\\u003C 1 month;\n* Pregnant or breasting-feeding women;\n* Allergic to Carrimycin tablets;\n* Active hepatitis B or hepatitis C infection;\n* Patients with HIV infection;\n* Patients with other contraindications considered unsuitable for participation in this study.","ALL","18 Years",{"count":58,"type":59},20,"ESTIMATED","INTERVENTIONAL",[62],"NA","This study aimed to investigate the efficacy and safety of Carrimycin tablets in hemophagocytic lymphohistiocytosis patients with Carbapenem-resistant infections.",[65,66],"Carbapenem Resistant Bacterial Infection","Hemophagocytic Lymphohistiocytoses","NOT_YET_RECRUITING","2023-08-04",{"date":70,"type":71},"2023-08-14","ACTUAL",{"date":73,"type":59},"2023-08-30",{"date":75,"type":59},"2026-12-30",{"name":5,"class":6},1]